This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (36)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Current and Evolving Strategies

Jack W. Kinch, MD; Ravin Davidoff, MBBCh

Arch Intern Med. 1995;155(13):1353-1360.

Abstract
We review the incidence of embolic events following cardioversion of atrial fibrillation, as well as the literature that forms the basis for the current strategy of anticoagulation before, and following, cardioversion to reduce the risk of post-cardioversion embolism. We evaluate a new strategy that uses transesophageal echocardiography to identify patients in atrial fibrillation without atrial thrombi who may be safely cardioverted without preceding anticoagulation and we also address the embolic event and anticoagulation issues in patients with atrial flutter. Cardioversion of atrial fibrillation to sinus rhythm is associated with a small but significant risk of thromboembolic events (average incidence, 1.5%; range, 0% to 7%). Anticoagulating these patients before cardioversion appears to significantly reduce this risk, and because of the delay in return of atrial contraction, anticoagulation should be continued for several weeks following cardioversion. The current guidelines for anticoagulating patients in atrial fibrillation who are to be cardioverted is based primarily on clinical observations, numerous uncontrolled case series, two retrospective trials, and one prospective nonrandomized controlled trial. Anticoagulation for 3 weeks before cardioversion followed by 4 weeks of anticoagulation after cardioversion is a theoretically sound and effective approach to reduce the risk of thromboembolic events. The use of transesophageal echocardiography to rule out thrombus and thus identify low-risk patients who may undergo cardioversion without preceding anticoagulation has been supported by several small studies that successfully used this strategy. However, the demonstration of a postcardioversion atrial and atrial appendage "stunning" suggests that anticoagulation needs to be given at the time of, and following, cardioversion. While promising, this transesophageal echocardiography—guided strategy for cardioversion of patients in atrial fibrillation requires more rigorous study before its routine use can be recommended. The current management of pure atrial flutter requires no anticoagulation before cardioversion; however, several clinical observations suggest theoretical risks for embolic events in these patients, thus further investigation of this strategy may be warranted.

(Arch Intern Med. 1995;155:1353-1360)

Author Affiliations
From the Evans Memorial Department of Clinical Research and the Division of Cardiology, Department of Medicine, Boston (Mass) University Medical Center Hospital.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Contemporary Management of Atrial Fibrillation: Update on Anticoagulation and Invasive Management Strategies
Crandall et al.
Mayo Clin Proc. 2009;84:643-662.
ABSTRACT | FULL TEXT  

Do Different Atrial Flutter Types Carry the Same Thromboembolic Risk?
Demir et al.
ANGIOLOGY 2005;56:593-599.
ABSTRACT  

Thromboembolic risk in atrial flutter. The FLASIEC (FLutterAtrialeSocietaIaliana diEcografiaCardiovascolare) multicentre study
Corrado et al.
Eur Heart J 2001;22:1042-1051.
ABSTRACT  

Early cardioversion of atrial fibrillation and atrial flutter guided by transoesophageal echocardiography: A single centre 8{middle dot}5-year experience
Corrado et al.
Europace 2000;2:119-126.
ABSTRACT  

Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation
Nattel
Cardiovasc Res 1999;42:298-308.
ABSTRACT | FULL TEXT  

Atrial Thrombi Resolution After Prolonged Anticoagulation in Patients With Atrial Fibrillation: A Transesophageal Echocardiographic Study
Corrado et al.
Chest 1999;115:140-143.
ABSTRACT | FULL TEXT  

Clinical Review : Update on Atrial Fibrillation: Restoration of Sinus Rhythm or Ventricular Rate Control?
Li and Hohnloser
J CARDIOVASC PHARMACOL THER 1998;3:185-194.
ABSTRACT  

Prevalence of Thrombus, Spontaneous Echo Contrast, and Atrial Stunning in Patients Undergoing Cardioversion of Atrial Flutter: A Prospective Study Using Transesophageal Echocardiography
Irani et al.
Circulation 1997;95:962-966.
ABSTRACT | FULL TEXT